Century Therapeutics (NASDAQ:IPSC) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Century Therapeutics from “sell” to “hold,” bringing the broader analyst consensus to “Hold” with an average price target of $4.75.
• Century Therapeutics opened at $1.94, with a market capitalization of approximately $351.3 million; shares have traded between $0.43 and $3.04 over the past year.
• The clinical-stage biotechnology company reported quarterly EPS of -$0.17, missing estimates by $0.06, while institutional investors own 50.2% of its stock and several funds recently established new positions.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

Several other research firms have also issued reports on IPSC. Weiss Ratings reiterated a "sell (d-)" rating on shares of Century Therapeutics in a research report on Thursday, July 2nd. Mizuho began coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They set an "outperform" rating and a $8.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Century Therapeutics currently has a consensus rating of "Hold" and an average target price of $4.75.

Century Therapeutics Price Performance

IPSC opened at $1.94 on Friday. The stock has a market capitalization of $351.28 million, a price-to-earnings ratio of -2.09 and a beta of 1.59. Century Therapeutics has a twelve month low of $0.43 and a twelve month high of $3.04. The company has a 50-day simple moving average of $2.10 and a 200 day simple moving average of $2.23.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.06). Sell-side analysts anticipate that Century Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Century Therapeutics during the 1st quarter valued at approximately $9,826,000. Commodore Capital LP acquired a new position in Century Therapeutics during the 1st quarter worth approximately $19,652,000. Rock Springs Capital Management LP bought a new position in Century Therapeutics in the 1st quarter valued at approximately $2,948,000. Versant Venture Management LLC bought a new position in Century Therapeutics in the 1st quarter valued at approximately $27,495,000. Finally, DV Trading LLC bought a new position in Century Therapeutics in the 1st quarter valued at approximately $3,164,000. Institutional investors own 50.20% of the company's stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.